This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Current health news covers Novo Nordisk's ongoing lawsuits over Wegovy copies, influencer Michelle Miller's push for GMOs, IO Biotech's narrowly missed cancer vaccine goal, and China's ban on Spanish ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

Health Hims & Hers Will Sell Wegovy-Like Weight Loss Drugs for $199 The telehealth company's stock surged after the announcement Bruce Gil, Quartz Published May 20, 2024 | Comments (13) 𝕏 ...

Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. For comparison, Wegovy costs around $1,350 per month, and Ozempic ...

Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Hims has thrived in the market for cheaper compounded versions of highly in-demand weight-loss drugs, such as Novo Nordisk's (NOVOb.CO) Wegovy. This was allowed by the U.S. Food and Drug ...

Lofty Valuations HIMS stock is deemed expensive by most metrics. The company trades at 6.6 times its sales, which is more than double the S&P 500’s 3.0 ratio. Its price-to-earnings ratio stands ...

Business Economy Health Technology Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future July 7, 2025 at 6:00 am Updated July 7, 2025 at 6:00 am ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.